Association between BNT162b2 or CoronaVac COVID-19 vaccines and major adverse cardiovascular events among individuals with cardiovascular disease.
Xuxiao YeTiantian MaJoseph Edgar BlaisVincent Ka Chun YanWei KangCeline Sze Ling ChuiFrancisco Tsz Tsun LaiXue LiEric Yuk Fai WanCarlos King-Ho WongHung Fat TseChung Wah SiuIan Chi Kei Ck WongEsther Wai Yin ChanPublished in: Cardiovascular research (2022)
Our findings showed no evidence of an increased risk of MACE after vaccination with BNT162b2 or CoronaVac in patients with CVD. Future research is required to monitor the risk after the third dose of each vaccine.